Faculty

Keith L. Knutson, Ph.D.

Clinical Studies

Clinical and Laboratory Characteristics of Long-Term Survivors of Advanced Ovarian Cancer (CLOAC) (CLOAC) Jacksonville, Fla.
The purpose of this study is to determine if long-term ovarian cancer survivors after receipt of a vaccine targeting folate receptor alpha will have persistent T cell and antibody responses to folate receptor alpha and will have broad evidence of systemic immune activation.
Ex Vivo Expansion Of Tumor Antigen-Specific T Cells For Adoptive T Cell Therapy (ACT-X) Jacksonville, Fla.
The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a blood sample from participants to study their immune cells’ reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.

A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer Rochester, Minn.
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Clinical and Laboratory Characteristics of Long-Term Survivors of Advanced Ovarian Cancer (CLOAC) (CLOAC) Rochester, Minn.
The purpose of this study is to determine if long-term ovarian cancer survivors after receipt of a vaccine targeting folate receptor alpha will have persistent T cell and antibody responses to folate receptor alpha and will have broad evidence of systemic immune activation.
MC1135, Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard chemotherapy in order to address whether the immunity is associated with the patient’s response to treatment.